Ipamorelin
Ipamorelin (10mg)
$120USD
Third-Party Tested
Independent lab verified
Batch-Specific CoA
Publicly accessible
YPB.263
Reference number
10mg
Lyophilized vial
Selective growth hormone secretagogue. Characterized by high receptor selectivity compared to other GHRP compounds.
Origin
Ipamorelin was developed by Novo Nordisk in the mid-1990s as a highly selective growth hormone releasing peptide (GHRP). It was designed through systematic modification of earlier GHRP compounds to achieve selectivity for growth hormone release without significant effects on ACTH, cortisol, or prolactin.
Research Lineage
Raun et al. published the foundational characterization of Ipamorelin in 1998, demonstrating its selectivity profile compared to GHRP-6 and GHRP-2. Subsequent pharmacokinetic studies by Anderson et al. established its in vivo activity profile. The compound has been studied in bone density, gastrointestinal motility, and growth hormone axis research.
Mechanism of Action
Ipamorelin acts as an agonist at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Unlike GHRP-6, it does not significantly activate the HPA axis or stimulate appetite-related pathways at GH-releasing doses. Its selectivity is attributed to its pentapeptide structure and specific receptor binding conformation.
Structural Notes
Pentapeptide. Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2. Molecular weight: 711.85 Da.
Key References
Raun K et al. Eur J Endocrinol. 1998;139(5):552-61.
Anderson LL et al. J Endocrinol. 2001;168(2):239-48.
Research Use Only. This product is intended for laboratory research purposes only. Not for human or veterinary use. Not for sale to minors.